End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
108 TWD | +0.47% | -4.42% | -.--% |
Sales 2024 * | 18.82B 578M | Sales 2025 * | 21.2B 651M | Capitalization | 82.51B 2.53B |
---|---|---|---|---|---|
Net income 2024 * | 4.84B 149M | Net income 2025 * | 6.2B 190M | EV / Sales 2024 * | 4.69 x |
Net Debt 2024 * | 5.71B 175M | Net Debt 2025 * | 1.56B 47.99M | EV / Sales 2025 * | 3.97 x |
P/E ratio 2024 * |
16.9
x | P/E ratio 2025 * |
13.8
x | Employees | - |
Yield 2024 * |
1.71% | Yield 2025 * |
2.4% | Free-Float | 48.47% |
Latest transcript on Lotus Pharmaceutical Co., Ltd.
1 day | +0.47% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 14-09-28 | |
I ling Tian
DFI | Director of Finance/CFO | - | 16-10-31 |
Ying Ming Yue
COO | Chief Operating Officer | - | 22-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 14-08-10 | |
Director/Board Member | 61 | 15-04-22 | |
Árni Harðarson
BRD | Director/Board Member | 57 | 14-08-10 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.17% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.45% | 233B | |
+6.04% | 201B | |
-10.51% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- 1795 Stock
- 1795 Stock